Previa Medical develops SEPSI-SCORE, an AI platform that analyses electronic medical records to detect and define sepsis infections, in some cases up to 48 hours before symptoms appear. The system is trained to interpret personal data from patients' electronic health records, including vital signs, and aims to reduce sepsis mortality and shorten hospital stays. The product was certified as a medical device in 2021. Previa plans to use the recent seed proceeds to fund a new multicentre clinical trial to further validate the technology, recruit users, expand product reach, and prepare for a full commercial launch. The company originated from an AI for health challenge launched in 2022 by Bpifrance and the French health ministry and has received grant funding from that initiative. The seed raise totaled €2.1 million and will support both clinical validation and commercialization efforts.

Total raised

$2M

Funding rounds

1

Latest round

Seed

Latest activity

Feb 2023